Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Ferroptosis As a Therapeutic Target in Subarachnoid Hemorrhage Publisher Pubmed



Dabbagh Ohadi MA1 ; Maroufi SF2, 3 ; Mohammadi MR4 ; Hosseini Siyanaki MR5 ; Khorasanizadeh M6 ; Kellner CP6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Departments of Pediatric Neurosurgery Children's Medical Center Hospital, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Neurosurgical Research Network (NRN), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  3. 3. Department of Neurosurgery, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Neurosurgery, University of Florida, Gainesville, FL, United States
  6. 6. Department of Neurosurgery, Mount Sinai Hospital, Icahn School of Medicine, New York City, NY, United States

Source: World Neurosurgery Published:2024


Abstract

Subarachnoid hemorrhage (SAH) is a cerebrovascular disorder with significant mortality and morbidity. Neural injury in SAH is mediated through a variety of pathophysiological processes. Currently available treatments are either nonspecific in targeting the basic pathophysiological mechanisms that result in neural damage in SAH, or merely focus on vasospasm. Ferroptosis is a type of programmed iron dependent cell death, which has received attention due to its possible role in neural injury in SAH. Herein, we review how intracellular iron overload mediates the production of reactive free radicals and lipid peroxidation through a variety of biochemical pathways in SAH. This in turn results in induction of ferroptosis, as well as exacerbation of vasospasm. We also discuss several therapeutic agents that have been shown to inhibit ferroptosis through targeting different steps of the process. Such agents have proven effective in ameliorating vasospasm, neural damage, and neurobehavioral outcomes in animal models of SAH. Human studies to test the safety and efficacy of intrathecal or parenteral administration of the inhibitors of ferroptosis in improving outcomes of SAH patients are warranted. There are currently a few ongoing clinical trials pursuing this therapeutic concept, the results of which will be critical to determine the value of ferroptosis as a novel therapeutic target in SAH. © 2023 Elsevier Inc.